Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our university and industry partners have expertise in many different fields, all critical to our mission to maximise the value of long-term health studies in the development of new treatments.




DPUK scientists in AstraZeneca are collaborators on the NTAD study, a large study using MEG scans of the brain in the search for the earliest signs of dementia.



DPUK scientists in Cambridge are working on a number of different areas including synaptic health, statistical methods, and wider ethical issues surrounding DPUK's work. 


DPUK scientists in Cardiff have developed the Genetics platform – a suite of data discovery tools for researchers looking to work with complex genetic data in their research.



DPUK scientists in Edinburgh contribute expertise in cognitive assessment, an important diagnostic tool for dementia. The team in Edinburgh have developed a new battery of tests in the UK's largest long-term health study. Edinburgh teams are also working on electronic health records and vascular elements to dementia.


DPUK scientists in Manchester are developing the DPUK wearables platform – technology which will allow researchers to make use of the important information collected by devices such as smart watches. Work to harmonise DPUK's MR-PET scanner network also takes place in Manchester. 

Araclon Biotech

DPUK scientists in Araclon Biotech are collaborators in our work in biomarker development for dementia.


 IXICO scientists provide expertise in the development and management of platforms for MRI and MEG data in the Deep and Frequent Phenotyping study.


DPUK scientists in Janssen are collaborators on the NTAD study, a large study using MEG scans of the brain in the search for the earliest signs of dementia.
Newcastle-University-logo DPUK scientists in Newcastle are investigating whether the characteristics of how people walk can be a useful early warning sign of Alzheimer's disease. Read the news story.
Somalogic Scientists in Somalogic have developed the SOMAscan technology which is being used in DPUK's work in biomarker development.
swansea_university_logo The DPUK team in Swansea has developed the Data Portal – a groundbreaking new resource of rich data for the research community.
GSK Research scientists with stem cell expertise and resources in GSK are collaborating with university-based researchers in the DPUK Stem cells network.
Imperial DPUK scientists at Imperial College London contribute expertise in brain scanning and form part of the DPUK Imaging network.
Kings College London DPUK scientists at Kings College London have assessed and developed recommendations for best practice in brain donation – a key area for dementia research. Other teams are investigating the role of heart health in dementia.
Oxford wide DPUK scientists in Oxford lead many aspects of the Deep and Frequent Phenotyping study, including  the investigation of cellular features of the disease development. Work to conduct repeat brain scans on a segment of the UK Biobank study is also led from Oxford.
UCL DPUK scientists in UCL work with the small, specialist studies of the cases of familial dementia. Other teams are working with the 'Insight 1946' study, conducting repeat advanced brain scans on a segment of this important group of people. 
Invicro Scientists in Invicro bring expertise in brain imaging to the DPUK partnership.
camcog_large_logo_rgb_1200_dpi.jpg Scientists in Cambridge Cognition contribute expertise in cloud-based cognitive testing to the DPUK partnership.
UniversityofExetercolour_logo.jpg Exeter is an important research site for the multicentre Deep and Frequent Phenotyping study.
Cognetivity_primary-colour.png Cognetivity's cognitive testing software is offered to DPUK cohort studies to enhance the data they collect.